HUWE1 and cancer: If inappropriate activation of a HECT E3 contributes to disease, the HECT E3 itself (e.g. overexpressed HECTH9 in cancer) or activators of the E3 activity (e.g. the E6/E6-AP interaction in cervical cancer) could be the targets of choice.